You are here

  • Home
  • Archive
  • Volume 9, Issue Suppl 2
  • 751 Neo-X-Prime bispecific antibodies targeting CD40 and tumor antigens promote cross-presentation of tumor exosome-derived neoantigen and induce superior anti-tumor responses compared to CD40 mAb

Article info

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Immune-Stimulants and Immune Modulators
751 Neo-X-Prime bispecific antibodies targeting CD40 and tumor antigens promote cross-presentation of tumor exosome-derived neoantigen and induce superior anti-tumor responses compared to CD40 mAb
Free

Authors

Citation

Hagerbrand K, Levin M, Schantz LV, et al
751 Neo-X-Prime bispecific antibodies targeting CD40 and tumor antigens promote cross-presentation of tumor exosome-derived neoantigen and induce superior anti-tumor responses compared to CD40 mAb
Journal for ImmunoTherapy of Cancer 2021;9:doi: 10.1136/jitc-2021-SITC2021.751

Publication history

  • First published November 10, 2021.
Online issue publication 
March 30, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.